Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 11570 6th St RANCHO CUCAMONGA CA 91730 |
Tel: | 1-909-9809484 |
Website: | https://amphastar.com |
IR: | See website |
Key People | ||
Mary Ziping Luo Chairman of the Board, Chief Operating Officer, Chief Scientist | Jack Yongfeng Zhang President, Chief Executive Officer, Chief Scientific Officer, Director | William J. Peters Chief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director |
Jacob Liawatidewi Executive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director | Rong Zhou Senior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd. |
Business Overview |
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others. |
Financial Overview |
For the fiscal year ended 31 December 2023, Amphastar Pharmaceuticals Inc revenues increased 29% to $644.4M. Net income increased 51% to $137.5M. Revenues reflect Pharmaceutical segment increase of 19% to $579.1M, API segment increase of 13% to $14.1M, United States segment increase of 30% to $635.2M. Net income benefited from Research and development decrease of 48% to $32.6M (expense). |
Employees: | 1,761 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2,445M as of Dec 31, 2023 |
Annual revenue (TTM): | $644.40M as of Dec 31, 2023 |
EBITDA (TTM): | $237.72M as of Dec 31, 2023 |
Net annual income (TTM): | $137.55M as of Dec 31, 2023 |
Free cash flow (TTM): | $145.34M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $333.21M as of Dec 31, 2023 |
Shares outstanding: | 48,095,862 as of Feb 22, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |